The Department of Surgery doesn’t just excel in the operating room. Through our extensive and innovative research programs, we are also focused on the development of new techniques and therapies that promote better outcomes and improve the quality of life for patients following surgery.
As part of that goal, the department’s surgeons are involved in groundbreaking clinical trials. In addition to their research value, clinical trials may also give patients access to new treatments that are not available anywhere else.
Learn more about our current clinical trials below or visit the Joint Clinical Trials Office at Weill Cornell Medicine and NewYork-Presbyterian.
In this study, we propose to collect urine, blood and stool at time of any biopsy as well as during their routine post-transplant outpatient visits. Samples will be stored in the Gene Expression Monitoring (GEM) laboratory funded by Dr.
This rearch study is for men and women who are admitted to the hospital for ST-elevated myocardial infarction (STEMI, or “heart attack”).
This study is being done to answer the following question:
- Diagnosis of Chronic Lymphocytic Leukemia
- No prior chemotherapy for Chronic Lymphocytic Leukemia
- Men and women age 18 years or older
- No major health complications other than Chronic Lymphocytic Leukemia
- Detailed eligibility reviewed when you contact the study team
This clinical trial is to evaluate an experimental (investigational) study drug in men or women who have been diagnosed with Primary Biliary Cholangitis (PBC). EDP-305 is considered to be experimental meaning it is not approved by the U.S.
- Men and women who are 18 years of age and older.
- Individuals with been diagnosed with Primary Biliary Cholangitis (PBC).
- Detailed eligibility reviewed when contacting the study team.
Exposure to radiation can impact immune cells that are present in the blood, such as lymphocytes. It is hypothesized that larger radiation fields and/or longer courses of radiation, result in greater decrease in immune cells.
1. Age ≥ 18
2. For cohort 1a and b: Prostate cancer subjects undergoing 9 week radiation
a. Biopsy-proven diagnosis of prostate adenocarcinoma
3. For cohort 2a : Breast cancer subjects undergoing standard fractionation RT of 5 weeks
a. Biopsy-proven diagnosis of invasive breast cancer, s/p breast surgery to negative margins, and requiring adjuvant breast and nodal RT
4. For cohort 2b: Breast cancer subjects undergoing PBI
a. Post-menopausal women defined as either 1) at least 2 years without menstrual period or 2) or patients older than 50 with serological evidence of post-menopausal status or 3) hysterectomized patients of any age with FSH confirmation of post-menopausal status.
b. Post-segmental mastectomy with negative margins
c. Clinically N0 or pN0 or sentinel node negative
Additional eligibility criteria reviewed when you contact the study team.